C-7ZR4Akero Therapeutics
FGF21 analogue, metabolic disease, MASH
modulatingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-7ZR4
C-7ZR4C-7ZR4FGF21 analogue, metabolic disease, MASH
0-100 chain-logic scale · 15 dimensions · scored on public evidence
When Akero’s stock dropped after a trial setback, why did RTW double down that same day? CEO Andrew Cheng joins RTW’s Rod Wong to share how he navigated the biotech storm, why he believed in efruxifermin (EFX,) and what’s next for liver disease treatment. PODCAST TEAM Producer: Devon Leaver Editor: Dominique Guerra Production Coordinator: YingYu Lin Featuring: Andrew Cheng, CEO of Akero Therapeutics, moderated by Roderick Wong, MD, Managing Partner and Chief Investment Officer RTW Investments. FOLLOW US Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website (https://www.rtwfunds.com/podcasts/?utm_source=YouTube&utm_medium=SocialMedia&utm_campaign=PodcastPage), for the latest updates and insights. To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify (https://open.spotify.com/show/09VhEfYUiSaLrGJJOUFvnw?si=0063127db5644751&nd=1&dlsi=8c2ac8fdb36b40a7), Apple Podcasts (https://podcasts.apple.com/us/podcast/the-rtw-podca
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.
The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in cirrhotic subjects with biopsy-proven F4 compensated NASH.
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in non-cirrhotic subjects with biopsy-proven F2 - F3 NASH.
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study administered for 16 weeks in subjects with biopsy proven F1 - F4 NASH.
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Akero Therapeutics, Inc. SEC 10-Q Report — TradingView News Search Products Community Markets Brokers More EN Get started News / TradingView / Akero Therapeutics, Inc. SEC 10-Q Report Akero Therapeutics, Inc. SEC 10-Q Report 2 min read Akero Therapeutics, Inc., a biopharmaceutical company focused on developing treatments for metabolic diseases, has released its Form 10-Q report for the third quarter of 2025. The report provides a comprehensive overview of the company's financial performance and operational progress, particularly in the development of its lead product candidate, efruxiferm
Akero Therapeutics, Inc. Asset Profile | Preqin Skip to main content Products Our products Preqin Pro Alternative assets data platform Private Markets Research Industry research Term Intelligence Benchmark LPA terms Preqin Benchmarks Industry's leading performance data Preqin Sustainability ESG data and insights Company Intelligence Companies & deals data Enterprise Data Solutions Flexible data delivery solutions Transaction Intelligence A $5.4tn transaction repository Client stories What our clients say Quick Links Our data Asset classes we cover Create a free account Newsletter Cont … r analysis Keep up with market trends Spot new business opportunities Benchmark fund terms Navigate private credit investing Quick Links Our data Asset classes we cover Create a free account Newsletter Contribute data Contact us Insights+ Private markets research Homepage Browse reports Search Search the research library Webinar recordings Join conversations with our analysts Meet the analysts Meet the team behind the reports Learn more Learn more about Private Markets Resear … r analysis Keep up with market trends Spot new business opportunities Benchmark fund terms Navigate private credit investing Insights+ Homepage Search Webinar recordings Meet the analysts Learn more News & content Homepage Events Free Benchmarks Data coverage map Preqin Profiles Preqin Academy Compensation calculator About Who we are Our corporate responsibility Partners Press hub Careers Contact us QuickLinks Our data Asset classes we cover Create a free account Newslett … ed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers. Request demo Akero Therapeutics, Inc. - overview Established 2017 Location South San Francisco, CA, US Primary Industry Biotechnology About Founded in 2017 and based in California, US, Akero Therapeutics, Inc. operates as a biotechnology that develops treatment of non-alcoholic steatohepatitis and other metabolic disor … go Pro Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more. Sign in Request demo Our Company Who We Are Our Corporate Responsibility Partners
Akero Therapeutics | Efruxifermin for MASH | Publications Contact Linked Twitter About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors Select Page About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors C
Foresite Capital --> --> Akero Therapeutics (Alumni) – Foresite Capital Strategy Portfolio People Careers News Blog Contact Us --> Back Portfolio Next NASDAQ: AKRO Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero’s lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MAS
Akero Therapeutics | Efruxifermin (EFX) for MASH | Company Contact Linked Twitter About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors Select Page About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors
Akero Therapeutics | Efruxifermin (EFX) for MASH | Contact Contact Linked Twitter About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors Select Page About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors … * General Careers Clinical Trials Business Development Media Message (Required) Submit Δ Our focus is on developing therapies to address serious metabolic diseases. View Therapeutic Areas About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Pipeline Development Pipeline Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers Our Culture Job Opportunities News Investors ©2026 Akero Ther
Akero Therapeutics | Efruxifermin for MASH | Pipeline Contact Linked Twitter About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors Select Page About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors Conta
%PDF-1.4 %���� %ABCpdf 11102 9 0 obj > endobj xref 9 14 0000000032 00000 n 0000001229 00000 n 0000001345 00000 n 0000001509 00000 n 0000001740 00000 n 0000001848 00000 n 0000001951 00000 n 0000002062 00000 n 0000002256 00000 n 0000002448 00000 n 0000002636 00000 n 0000002757 00000 n 0000004350 00000 n 0000006717 00000 n trailer ] /Info 8 0 R /Prev 16249 /Root 10 0 R /Size 23 /Source (WeJXFxNO4fJduyUMetTcP9+oaONfINN4+d779+z/WV1lxEieI1zHTI8wLVVf9XNPB9khgm8VtCFmyd8gIrwOjQRAIjPsWhM4vgMCV\ 8KvVF/K8lfHuZ4YXZq6OX6QZzwYc/tRXeVy3SInGEg=) >> startxref 0 %%EOF 10 0 obj > endobj 11 0 obj > stream x�c```"
10-K 1 akro-20201231x10k.htm 10-K Table of Contents 33 ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ​ FORM 10-K ​ (Mark One) ​ ⌧      ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ​ For the fiscal year ended December 31, 2020. ​ OR ​ ◻       TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ​ For the transition period from      … 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth com … expected timelines during the ongoing COVID-19 pandemic; ● our ability to submit information to regulatory authorities that supports initiation of our planned Phase 2b clinical trial of EFX in cirrhotic NASH patients with F4 fibrosis during the ongoing COVID-19 pandemic; ● the potential for COVID-19 or other pandemic, epidemic or outbreak of an infectious disease, including COVID-19, to disrupt our business plans, product development activities, ongoing clinical t … welve years of market exclusivity from the approval date of a Biologics License Application, or BLA, in the United States. Our management team has extensive experience in drug discovery, development and commercialization, and has been involved in the approvals of more than 20 medicines. Our Chief Executive Officer, Andrew Cheng, MD, PhD, previously Chief Medical Officer at Gilead, was responsible for clinical development for Gilead's HIV program. Our Chief Development Off … io relating to EFX includes twelve issued U.S. patents, one pending U.S. patent application, and issued and pending foreign counterpart patents in Europe, Asia, Canada, Australia, and Mexico. Seven issued U.S. patents include claims directed to the EFX product, the FGF21 polypeptide component of the EFX product, nucleic acids encoding the product
Akero Therapeutics | Terms of Use Contact Linked Twitter About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors Select Page About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors Contact Linked Twitter Te … IAL DAMAGES. ACCORDINGLY, IN SUCH STATES, SOME OF THE ABOVE LIMITATIONS MAY NOT APPLY TO YOU OR BE ENFORCEABLE WITH RESPECT TO YOU, AND THE LIABILITY OF THE COMPANY PARTIES SHALL BE LIMITED TO THE GREATEST EXTENT PERMITTED BY LAW. 4. Indemnification. You agree to defend, indemnify, and hold harmless the Company Parties from and against any claims, actions or demands, including, without limitation, reasonable legal and accounting fees, arising or resulting from your breach of … nia, without respect to its conflict of laws provisions. You expressly agree to submit to the exclusive personal jurisdiction of the state and federal courts sitting in the City of San Francisco in the State of California. If any provision of this Agreement is found to be invalid by any court having competent jurisdiction, the invalidity of such provision shall not affect the validity of the remaining provisions of this Agreement, which shall remain in full force and effect.
Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Th … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update May 12, 2025 | 13 min read Twitter LinkedIn Facebook Email Print Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks o … cebo. The primary histology endpoint, for Cohort 1 only, to support a potential application for accelerated approval, is the proportion of patients experiencing ≥1-stage fibrosis improvement and resolution of MASH after 52 weeks of treatment. All patients in Cohort 1 and Cohort 2 will be evaluated for long-term clinical outcomes for up to 240 weeks of treatment. The SYNCHRONY Outcomes study is evaluating the safety and efficacy of 50mg EFX in patients with compensated cirrhos … equivalents and short and long-term marketable securities will be sufficient to fund its current operating plan into 2028. Research and development expenses for the three-month period ended March 31, 2025 were $69.6 million, compared to $50.7 million for the comparable period in 2024. These increases were attributable to higher expenses associated with the ongoing Phase 3 SYNCHRONY Histology , Real-World , and Outcomes studies, and manufacture of clinical supplies for Phase 3 … ory developments in the United States and foreign countries; Akero’s ability to fund operations; as well as those risks and uncertainties set forth more fully under the caption "Risk Factors'' in Akero’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission (SEC) as well as
Libette Luce- Akero Therapeutics VP Head of Regulatory Affairs - Biotech Builders | Podcast on Spotify
Akero Therapeutics' efruxifermin treats liver disease, says RTW Podcast | RTW Investments, LP posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue t
National Disability Rights Lea… - Disability Matters - Apple Podcasts Search Home New Top Charts Search October 19, 2021 56 min National Disability Rights Leader, Jonathan Young Disability Matters Play Joyce welcomes National Disability Rights Leader and the originator of Disability Mentoring Day, Jonathan Young to the show. Jonathan served at the White House during the Clinton administration as the Disability Liaison to the President. Currently, Jonathan is the Chief Operating Officer and Co-Founder of Akero Therapeutics in South San Francisco. Akero Therapeutics is a clinical-stage cardio-me
Q3 Earnings Are Here, Novo Ditches Cell Therapy but Buys Akero, Gov’t Shutdown Hits CDC-BioSpace Home Home Podcasts Podcasts Library Cancel Sign in Q3 Earnings Are Here, Novo Ditches Cell Therapy but Buys Akero, Gov’t Shutdown Hits CDC BioSpace Oct 15 2025 • 27 mins Johnson & Johnson kicked off Q3 earnings season on Tuesday with the announcement that it is splitting its orthopedics and medtech operations and that it has yet to reach a drug pricing deal with the White House, though CEO Joaquin Duato did say those discussions are ongoing. In advance of its Nov. 5 earnings call, Novo Nordisk, … ear. And a recent report on breakthrough designations shows that the regulatory award often leads to an FDA greenlight. On the legislative front, the BIOSECURE Act is back, as a slimmed down version passed the Senate last week as part of the defense spending bill. The latest version of BIOSECURE, which is meant to distance American biopharma from Chinese collaborators, doesn’t name specific companies as previous iterations did and must still gain the Senate’s support. You Mig
From drop to double: Akero’s s…–The RTW Podcast – Apple Podcasts Search Home New Top Charts Search 14 July 2025 14 min From drop to double: Akero’s surging stock The RTW Podcast Play When Akero’s stock dropped after a trial setback, why did RTW double down that same day? CEO Andrew Cheng joins RTW’s Rod Wong to share how he navigated the biotech storm, why he believed in efruxifermin (EFX,) and what’s next for liver disease treatment. PODCAST TEAM Producer: Devon Leaver Editor: Dominique Guerra Production Coordinator: YingYu Lin Featuring: Andrew Cheng, CEO of Akero Therapeutics, moderated by
Akero Therapeutics: Developing a drug for advanced-stage MASH patients | RTW Investments, LP posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to joi … , Altagenics Launch; Cos. Raise Millions; Kernal Biologics Awarded $48M ARPA-H Grant #healthcare #biotech #lifescience #HealthTech #AI 1 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in BioMaP-Consortium | Biopharmaceutical Manufacturing Preparedness Consortium 1,430 followers 8mo Report this post As demand for life-saving therapeutics grows, biomanufacturers face complex challenges in expanding capacity while maintaining quality. In BioProcess I
CEO Andrew Cheng talks MASH program with Roderick Wong | Akero Therapeutics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you
Akero Therapeutics acquired by Novo Nordisk for $5.2B - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies Mi
Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
8-K 1 tm2022247-1_8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2020 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission File Number) (I … ments over three years until fully vested on the third (3rd) anniversary of the grant date, subject to the continued service of Mr. Heyman on the Board. Also in connection with his election to the Board, Mr. Heyman will enter in to the Company’s standard form of indemnification agreement, a copy of which was filed as Exhibit 10.4 to Amendment No. 1 to the Company’s Registration Statement on Form S-1 (File No. 333-231747) filed with
%PDF-1.7 %���� 1 0 obj >/Metadata 736 0 R/ViewerPreferences 737 0 R>> endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj >/Font >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 5 0 R/Group >/Tabs/S/StructParents 0>> endobj 5 0 obj > stream x��[ߏ]��~7��� o��X �T7|�:H�7�[ �m;�8ٽdž/�����q6�����]e�eh x#��l����ozN�b���9G�A=U�u cuB�v*فȵ�� m B9���O�)��sG���qK�!Soa3y�0�.��v ��g�Ϝ�.;��1�s'� ��`�j�v�n_r���ԂJ Q����\*��n+iQ�b1� �}��'嗑��� "(z��@6�A��ǧ��� 8� �@��cT�e�Wvsc��j��J(�l��~r���% v����7L�#�j@��ƃp�D$.ZQ)�i�>��y:�$f�"7��a ���eU ��kg�U �wRQ … 1� �~���>��y�I6�k� $����C~� kBࢡ>�W#�_M� ��YЃ�"jhK �GpY� b�2�ZB), G��� �x��rFP�*�[� XS�OUqX��&�u�>Yⵣ��v��zκ��� �Osګ��)��=)۰�_E6�og�# �Z�t�B�zӦ p��zU�+�� ��*�zc֒{_��I�j]sw2��n,$�9+�3���}OL���X$��Xf �X� K�o��l����QWa(�E�%k�y�?!�2���u\˪iDE$�����U�}B��b��{�����r��"��'oL�U�{ic\�7zp�����{���B�GjE� �Y��>}��ڭ�9X� ��W �*�bq�tdcک �g��_]�,�h���X�x�$���[j���v�o� ����&��0>�0+E�,k�HS��&�ʊ%[��1!8�V��K�_4�ީ� ��{ R������"�2_��J�� @�v��9��o��]@�� &' ��n���� �� ��
8-K 1 tm2014246-1_8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2020 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Iden
Akero Therapeutics Appoints Mark Iwicki to its Board of Directors Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Gall … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Novo Nordisk buys Akero Therapeutics for $4.7 billion | Kyle LaHucik posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree … fusion protein LBL-047, which has received an Investigational New Drug ( #IND ) application approval in the United States and IND acceptance in mainland #China . Under the terms of the agreement, Dianthus will pay VivaGlobe $38 million in upfront fees (including $30 million for initial and near-term milestone payments, as well as an additional $8 million milestone payment upon the initiation of Phase 1 clinical trials led by Dianthus) to secure exclusive rights for the global … stocks #biotech #investing #mergersandacquisitions #pharma #patentcliff Biotech Fund Beating 92% of Peers Sees More M&A Deals to Come bloomberg.com 40 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in NOTRELOAD AI 221 followers 8mo Report this post Maxim doubles Rani Therapeutics price target to $10 after $1B+ Chugai partnership validates RaniPill technology. Company secures $60M funding to advance oral drug delivery platform. https:/
Akero Therapeutics | EFX for MASH | Patients & Caregivers Contact Linked Twitter About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors Select Page About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investo … eneral Criteria . Although Akero retains sole discretion in deciding whether to grant an expanded access request, the following criteria will guide evaluation of requests: The condition or disease being studied is serious or life-threatening and there are no available alternative treatments; The patient is not eligible for an ongoing or planned Akero-sponsored clinical trial; There must be sufficient clinical data to identify an appropriate dose for the proposed use; The pote
%PDF-1.4 %�쏢 %%Invocation: gs -sDEVICE=pdfwrite -dPDFSETTINGS=/printer -dCompatibilityLevel=1.4 -dColorConversionStrategy=/LeaveColorUnchanged -dDownsampleMonoImages=true -dDownsampleGrayImages=true -dDownsampleColorImages=true -dAutoFilterColorImages=true %%+ -dAutoFilterGrayImages=true -dColorImageFilter=/FlateEncode -dGrayImageFilter=/FlateEncode -dCompressFonts=true -dColorImageResolution=150 -dGrayImageResolution=150 -dMonoImageResolution=150 -dNOPAUSE -dQUIET -dBATCH ? ? ? 6 0 obj > stream x��}Ys G�&��M/�;�k6��0k��%�y ����zDRMR��j� GDA8��������NDF����Um4�Yqx ����ϋl�/2�g����W?U٢
Novo Nordisk Enters $4.7 Billion Definitive Agreement with Akero Therapeutics | PharmExec --> --> News News Academy Multimedia Editorial Podcasts Editorial Videos Peer Exchange Profiles in Medicine Shorts Conferences Conference Coverage Conference Listing More Publications Pharmaceutical Executive Partner Perspectives Resources Content Engagement Hubs E-Books Events Sponsored Podcasts Sponsored Videos Webcasts Whitepapers Subscribe My Account News Academy Multimedia Conferences Publications Partner Perspectives Resources Subscribe Corporate Communications Press Releases Executive Roundtable Ex
Akero to be acquired by Novo for $54/share plus CVR | AKRO SEC Filing - Form PREM14A --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Cry … ined the transaction is advisable and fair and recommends voting FOR the Merger Proposal, the non-binding Compensation Proposal, and the Adjournment Proposal. Closing requires approval by a majority of outstanding shares. Appraisal rights are available for stockholders who comply with Delaware law procedures. Following closing, Akero’s shares will be delisted and deregistered. Equity awards will be treated in cash at the Closing Consideration (plus a CVR per underlying share) … nalyst neutral Board seeks approval for cash-and-CVR sale of Akero to Novo. The proposal would convert each Akero share into $54.00 cash plus one CVR, with Akero becoming a wholly owned Novo subsidiary. Approval requires a majority of outstanding shares, and the board unanimously recommends adoption. After closing, shares are expected to be delisted and deregistered. Mechanically, equity awards are cashed out at the Closing Consideration, with CVRs added per underlying share, … other than the Registrant)   Payment of Filing Fee (Check all boxes that apply):   ☐ No fee required.   ☐ Fee paid previously with preliminary materials. ☒ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. TABLE OF CONTENTS PRELIMINARY PROXY STATEMENT - SUBJECT TO COMPLETION   Akero Therapeutics, Inc. 601 Gateway Boulevard, Suite 350 South San Francisco, CA 94080 … his letter. At the Special Meeting, you will be asked to consider and vote on a proposal to adopt the Agreement and Plan of Merger (which we refer to, as it may be amended from time to time, as the “Merger Agreement”), dated October 9, 2025, by and among Akero, Novo Nordisk A/S, a Danish aktieselskab (which we refer to as “
Verified Wuxi Akero Power Manufacturers and Suppliers | HKTDC Sourcing Suppliers Products Services Suppliers Please enter a valid keyword with 2 or more characters / numbers. Confirm Become a Supplier My Sourcing Become a Supplier Shopping Cart Request For Quotation List Message Centre Notification Favourites List Browsing History Scan2Match - Exhibitor List Top Picks NewsBites Sourcing Support Sitemap Become a Supplier Register for Sourcing Suppliers Products Services Suppliers Please enter a valid keyword with 2 or more characters / numbers. Confirm Please enter a valid keyword with 2 or mor … onic Gadgets Electronic Switch Home Control System Home Security System IoT Iot Application Iot Device LED Test Kit Lux Meter Network Repeater Power Repeater Repeater Router Repeater Satellite Equipment Signal Repeater Smart Home Smart Home System Switch Wifi Repeater Wireless Doorbell Wireless Repeater Consumer Electronics Accessories Consumer Electronics Gadgets DAB Antenna Door Door Accessories Door Bell Door Viewer Electric Socket Electric Switch Electrical Plug Electrica
Akero Therapeutics | Efruxifermin for MASH | Publications Contact Linked Twitter About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors Select Page About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors C
%PDF-1.3 %��������� 3 0 obj > stream x��ݖǑ�����vMP�ɒ53;k�i{|v���(Rk�[��/7ϰg��}��"� U���( w7���� �Y��X~���'?4��?,�� �Z�6m~�?��z����,�t�n�+~m���9,��Y����f�,�~�|��h���,�4�_�iخ���f�������D'am��@����Ca� ��fl��6��L͕���1�_2lӽ���*DŽJQnߟssL͡����f��P�6���߽� ���� �Y �n3 t��TE�M����]�VE0Q��6��ԕ|�/�7���l�����]���P�mW{�~�`�E*��w���=��Y��U�\F}���7^�_P ٷi���md!1�,,��J����~E88���f�_8��+��m��V��@V��W#�饬i(ж(I�oW��Y�Y6���GX��V�Z�~��6[� �n�n��L#���h���t��z����Øͪ�7�n_H�������9h�判�p�)�{�������~ӵ;� ��?���v�]{X?Z��E�;6�U�߸{��w�����,'�҄� À�a�[���� \I�P�Ŝ�v�l�U��ˆ�f��(�W�nw2�
We are announcing an agreement with Akero Therapeutics to acquire the company and its promising candidate in phase 3 development for metabolic dysfunction-associated steatohepatitis (MASH). The… | Novo Nordisk | 25 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your ch
Insider Sale: Chief Operating Officer of $AKRO Sells 586 Shares | Quiver Quantitative --> Skip to Main Content MEMORIAL DAY API SALE 50% off your first year of Quiver API ... Use Promo Code: MEM50 Quiver API --> × Get a Free Trial on Quiver Premium Today! Upgrade Now Upgrade × Get Email Alerts On AKRO Stock Enter your email to receive free breaking news alerts and insights related to AKRO. Sign Up Now (Free) Home Datasets Most Popular Politician Search Congress Trading 2026 Midterm Elections Donald Trump Stock Trades Election Fundraising Insider Trading Government Contracts Corpora … actions, check out Quiver Quantitative's insider trading dashboard. $AKRO Hedge Fund Activity We have seen 140 institutional investors add shares of $AKRO stock to their portfolio, and 147 decrease their positions in their most recent quarter. Here are some of the largest recent moves: AVORO CAPITAL ADVISORS LLC added 3,500,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $186,760,000 WELLINGTON MANAGEMENT GROUP LLP removed 2,526,294 shares (-42.6%) from the
AKRO Insider: COO Jonathan Young Sells Shares, Acquires 12,500 Options | AKRO Insider Trading --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI S
Akero Therapeutics COO Jonathan Young Sells 12,500 Shares — TradingView News Search Products Community Markets Brokers More EN Get started News / TradingView / Akero Therapeutics COO Jonathan Young Sells 12,500 Shares Akero Therapeutics COO Jonathan Young Sells 12,500 Shares Less than 1 min read Reporter Name Young Jonathan Relationship Chief Operating Officer Type Sell Amount $576,035 SEC Filing Form 4 Jonathan Young, Chief Operating Officer of Akero Therapeutics, sold 12,500 shares of common stock on September 2, 2025, under a Rule 10b5-1 trading plan. The transactions occurred at weighted a
Akero (AKRO) Form 4: COO Jonathan Young Sells 12,500 Shares | AKRO Insider Trading --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypt
Jonathan Young PhD - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Profile Jonathan Young PhD Chief Executive Officer at Akero Therapeutics, Inc. Jonathan Young PhD 's Executive Work History Current Chief Executive Officer , Chief Executive Officer Equilar on 04/24/2026 Akero Therapeutics, Inc. Past To view Jonathan Young P
EX-32.1 6 akro-ex32_1.htm EX-32.1 EX-32.1 EXHIBIT 32.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Andrew Cheng, certify pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Akero Therapeutics, Inc. for
Insider Sale: President and CEO of $AKRO Sells 30,000 Shares | Quiver Quantitative --> Skip to Main Content MEMORIAL DAY API SALE 50% off your first year of Quiver API ... Use Promo Code: MEM50 Quiver API --> × Get a Free Trial on Quiver Premium Today! Upgrade Now Upgrade × Get Email Alerts On AKRO Stock Enter your email to receive free breaking news alerts and insights related to AKRO. Sign Up Now (Free) Home Datasets Most Popular Politician Search Congress Trading 2026 Midterm Elections Donald Trump Stock Trades Election Fundraising Insider Trading Government Contracts Corporate … actions, check out Quiver Quantitative's insider trading dashboard. $AKRO Hedge Fund Activity We have seen 138 institutional investors add shares of $AKRO stock to their portfolio, and 126 decrease their positions in their most recent quarter. Here are some of the largest recent moves: AVORO CAPITAL ADVISORS LLC added 3,500,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $186,760,000 WELLINGTON MANAGEMENT GROUP LLP removed 2,526,294 shares (-42.6%) from the
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Andrew Cheng, M.D., Ph.D., - Expedition Therapeutics Skip to content About Us Science Team Media Investors Contact About Us Science Team Media Investors Contact Board of Directors Management Board of Directors Scientific Advisory Board Management Board of Directors Scientific Advisory Board Andrew Cheng, M.D., Ph.D., Board Chairman Dr. Andrew Cheng has served as Akero’s president and chief executive officer since September 2018. Before joining the company, he served for 19 years at Gilead Sciences, where his last role was chief medical officer. During his tenure, he was responsible for t … iversity College of Physicians and Surgeons. He completed his internal medicine residency at UCLA and was board certified in internal medicine. < Prev Yi Larson, M.Eng., MBA Jonathan Leff, M.D. Next > About Us Science Team Media Investors Contact About Us Science Team Media Investors Contact Cookie Policy Privacy Statement Cookie Policy Privacy Statement © Expedition Therapeutics Inc., 2026 Site by BKW
Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion | Akero Therapeutics, Inc. | Leighanne Oh, M.S. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join o
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Akero Therapeutics' CEO Andrew Cheng comments on today's 96 week MASH data and the future of efruxifermin. He describes the F4 patient population, and dicusses the efficacy… | BiotechTV LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices … ket position, financial stability, and undervaluation, noting enough capital to fund operations for the next two years. ➡️ CEO Brian Lian points to growing interest in the #MASH (metabolic-associated steatohepatitis) space, with major pharma deals from #Roche , #GSK , and #Novartis spotlighting its strategic value, especially for Viking’s #VK2809 asset. ➡️ Overall, analysts view #Viking as a well-backed company with a promising pipeline, strong clinical programs, and valuable
Sign up Log in Akero Therapeutics Overview Jobs ( 0 ) No open jobs right now Akero Therapeutics 's open jobs will appear here Live anywhere, work everywhere. Sign up for free Company About Remote Careers Support Contact us For job seekers Sign up with Remote Jobs Browse remote jobs Remote work Remote jobs by category Copyright © 2024. Remote Technology, Inc. All rights reserved. Privacy Policy Cookie Policy Terms of Use Akero Therapeutics Overview Jobs ( 0 ) About Akero Therapeutics Akero Therapeutics Website akerotx.com Akero Therapeutics | Remote
Skip to content How It Works Pricing Blog Events Partners Search orgs, people, news, resources... ⌘K Sign In Get Started → Search organizations, people, news, resources, and content... / How It Works Pricing Blog Events Partners Sign In Get Started → Loading organizations... The OS for early-stage founders from day zero to raise. Subscribe Product How It Works Pricing Partners Resources Blog Events Contact Company About Privacy Terms © 2026 Startup Intros, Inc. San Francisco, CA · Made for Founders Akero Therapeutics: Funding, Team & Investors | Startup Intros Home / Organizations / Akero
Akero Therapeutics Reports Recent Highlights and Second Quarter 2019 Financial Results Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All V … in the United States and foreign countries; the company's ability to fund operations; as well as those risks and uncertainties set forth more fully under the caption "Risk Factors" in the final prospectus dated June 19, 2019 and filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, with the United States Securities and Exchange Commission (SEC) and elsewhere in Akero's filings and reports with the SEC. All forward … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Jobs at Akero Therapeutics | Foresite Capital You are using an outdated browser. Please upgrade your browser to improve your experience and security. Strategy Portfolio People Careers News Blog Contact Us Home Strategy Portfolio People Careers News Blog Contact Us Foresite Labs Investor Login Terms Privacy Policy Powered by Consider Privacy Terms © 2026 Foresite Capital Management, LLC. Strategy Portfolio People Careers News Blog Contact Us Foresite Labs Investor Login Terms Privacy Policy
Akero Therapeutics | EFX for MASH | Our Culture Contact Linked Twitter About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors Select Page About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors Contact Lin … from an official company email address. If you receive any suspicious messages, submit a report to the Federal Trade Commission. We’re looking for talented individuals driven to make a difference for patients. View Open Positions About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Pipeline Development Pipeline Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers Our Culture Job Opportun
Akero Therapeutics Appoints Scott Gangloff as Chief --> Accessibility: Skip TopNav Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer April 30, 2024 08:00 ET | Source: Akero Therapeutics Inc. Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, today announced the appointment of Scott Gangloff as Chief Technology Officer. "I am delighted to welcome Scott to Akero. His depth of experien … n of the combination drug-device product for potential regulatory authorization application and subsequent commercialization.” About Efruxifermin Efruxifermin (EFX), Akero’s lead product candidate for MASH, is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX appears to reduce liver fat and i … ory developments in the United States and foreign countries; Akero’s ability to fund operations; as well as those risks and uncertainties set forth more fully under the caption "Risk Factors" in Akero’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission (SEC) as well as discussions of potential risks, uncertainties and other important factors in Akero’s other filings and reports with the SEC. All forw
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
8-K false 0001744659 --12-31 0001744659 2025-10-08 2025-10-08     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2025     AKERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)       Delaware   001-38944   81-5266573 (State of incorporation)   (Commission File No.)   (IRS Employer Identification No.) … and conditions of the Merger Agreement, if the Company receives an acquisition proposal that did not result from the Company’s breach of its no-shop covenants, and following such receipt, the Board of Directors determines in good faith, after consultation with its outside legal counsel, that such acquisition proposal is or could lead to a Superior Offer and the failure to terminate the Merger Agreement and change its recommendation of the Merger to the Company’s … elated closing conditions to not be met), (ii) prior to any such termination, a proposal to acquire 50% or more of the Company’s stock or assets is communicated to the Board of Directors or publicly disclosed and has not been withdrawn, and (iii) the Company enters into an agreement for, or consummates, a transaction involving an acquisition of 50% or more of the Company’s stock or assets within 12 months of such termination. The Merger Agreement further prov … which was filed with the SEC on February 28, 2025 and (ii) the “Proposal 1 – Election of Class III Directors,” “Executive Compensation,” and “Principal Stockholders” sections of Akero’s proxy statement for its 2025 annual meeting of stockholders, which was filed with the SEC on April 28, 2025 , and will be contained in the proxy statement to be filed by Akero in connection with the proposed transaction. Any c … Administration’s (“ FDA ”) approval of Akero’s new drug application for efruxifermin for the treatment of metabolic dysfunction-associated steatohepatitis, Akero’s ability to commercialize current and future product candidates, the anticipated timing of closing of the Transaction and the accuracy of any assumptions u
Jobs at Akero Therapeutics Current openings at Akero Therapeutics Create a Job Alert Level-up your career by having opportunities at Akero Therapeutics sent directly to your inbox. Create alert There are no current openings. Powered by Greenhouse
Akero Therapeutics | EFX for MASH | Our Culture Contact Linked Twitter About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors Select Page About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors Contact Lin … from an official company email address. If you receive any suspicious messages, submit a report to the Federal Trade Commission. We’re looking for talented individuals driven to make a difference for patients. View Open Positions About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Pipeline Development Pipeline Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers Our Culture Job Opportun
News | Akero hires Andrew Cheng as CEO | Versant Ventures Home Discovery Engines Team Portfolio Offices News ← View News Sep 11, 2018 Andrew Cheng, MD, PhD Joins Akero Therapeutics as President and Chief Executive Officer Download PDF Media Contact Steve Edelson (415) 801-8088 [email protected] LP Access News Contact Us Site Map Privacy Terms © 2026 Versant Ventures. a FINE site.
Akero Therapeutics Appoints Yuan Xu to its Board of Directors | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
%PDF-1.4 %���� 1 0 obj > endobj 2 0 obj > stream ����JFIF,,���Photoshop 3.08BIMw x& (PRNewsfoto/Akero Therapeutics, Inc.) Z CAMBRIDGE t}This image must be used within the context of the news release it accompanied. Request permission from issuer for other uses. e PHand-out _MA i Akero-Logo Akero-Logo sCNW 720180625 nAkero Therapeutics, Inc. g zCN ( See Release PRNArchive_1Year|WebsiteDistribu ��C ��C ��=���
Akero Therapeutics | EFX for MASH | Job Opportunities Contact Linked Twitter About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors Select Page About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors Conta
Apple Tree Partners | Akero Therapeutics to be Acquire... A T P About Team Portfolio ATP R&D News Locations Contact Oct 09, 2025 Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion Share Shareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share Advances Akero’s Mission of Bringing Novel Therapies to Patients with High Unmet Medical Needs SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (“Akero”) (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metab … ich was filed with the SEC on February 28, 2025 and (ii) the “Proposal 1 – Election of Class III Directors,” “Executive Compensation,” and “Principal Stockholders” sections of Akero’s proxy statement for its 2025 annual meeting of stockholders, which was filed with the SEC on April 28, 2025 , and will be contained in the proxy statement to be filed by Akero in connection with the proposed transaction. Any chang … he U.S. Food and Drug Administration’s approval of Akero’s new drug application for efruxifermin for the treatment of metabolic dysfunction-associated steatohepatitis, Akero’s ability to commercialize current and future product candidates, and the anticipated timing of closing of the Transaction. Forward-looking statements are subject to certain risks, uncertainties, or other factors that are difficult to predict and could cause actual events or results to d … r waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the Transaction; the effects of the Transaction on relationships with employees, other business partners or governmental entities; the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; that Parent may not realize the potential benefits of the Transaction; other business effects,
Akero Therapeutics | EFX for MASH | Our Culture Contact Linked Twitter About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors Select Page About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors Contact Lin … from an official company email address. If you receive any suspicious messages, submit a report to the Federal Trade Commission. We’re looking for talented individuals driven to make a difference for patients. View Open Positions About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Pipeline Development Pipeline Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers Our Culture Job Opportun
Akero Therapeutics | EFX for MASH | Job Opportunities Contact Linked Twitter About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors Select Page About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors Conta … from an official company email address. If you receive any suspicious messages, submit a report to the Federal Trade Commission. Positions Available at Akero Having fun is a key ingredient to our success. Learn About Our Culture About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Pipeline Development Pipeline Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers Our Culture Job Opportuni
Akero Therapeutics Strategy and Business Model Skip to content Skip content FIND YOUR CONSULTANT JOIN OUR COMMUNITY Services Strategy Operations Organization Marketing Finance Sales Artificial Intelligence (AI) Interim/Fractional Executives Enterprise Resource Planning (ERP) Associate-level Support Board Recruiting Pro bono Industries Resources Locations Insights Podcast Blog Books by members Umbrex Presents PowerPoint Templates About What we do Consultant directory Press Contact For consultants Join our Community How to start your own practice Events Resources Podcast Members’ forum Umb … ur own practice Events Resources Podcast Members’ forum Umbrex Consulting Fellowship Consultant directory Services Strategy Operations Organization Marketing Finance Sales Artificial Intelligence (AI) Interim/Fractional Executives Enterprise Resource Planning (ERP) Associate-level Support Board Recruiting Pro bono Industries Resources Locations Insights Podcast Blog Books by members Umbrex Presents PowerPoint Templates About What we do Consultant directory Press Contact … ur own practice Events Resources Podcast Members’ forum Umbrex Consulting Fellowship Consultant directory FIND YOUR CONSULTANT JOIN OUR COMMUNITY Services Strategy Operations Organization Marketing Finance Sales Artificial Intelligence (AI) Interim/Fractional Executives Enterprise Resource Planning (ERP) Associate-level Support Board Recruiting Pro bono Industries Resources Locations Insights Podcast Blog Books by members Umbrex Presents PowerPoint Templates About What … ur own practice Events Resources Podcast Members’ forum Umbrex Consulting Fellowship Consultant directory Services Strategy Operations Organization Marketing Finance Sales Artificial Intelligence (AI) Interim/Fractional Executives Enterprise Resource Planning (ERP) Associate-level Support Board Recruiting Pro bono Industries Resources Locations Insights Podcast Blog Books by members Umbrex Presents PowerPoint Templates About What we do Consultant directory Press Contact … ur own practice Events Resources Podcast Members’ forum Umbrex Consulting Fellowship Consultant directory Company Profiles > Akero Therapeutics Strategy and Business Model Akero Therapeutics Strategy and Business Model Executive Overview Akero Therapeutics is a South San Francisco-based clinical-stage biopharmaceutical company founded in
Andrew Cheng, MD, PhD Joins Akero Therapeutics as President and Chief Executive Officer Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Akero to be acquired by Novo Nordisk for $5.2B | Jason Russell posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Lin … trategic Move Global healthcare giant Novo Nordisk has announced an unsolicited proposal to acquire Metsera , Inc., marking a bold move to strengthen its leadership in metabolic and peptide-based therapies. 💡 The proposed deal values Metsera at $6.5 billion, with an additional $2.5 billion in contingent value rights (CVRs) tied to future clinical and regulatory milestones. Through this acquisition, Novo Nordisk aims to leverage Metsera’s incretin and non-incretin analogue pe … nt: $4.7 billion • Contingent Payment: Up to $0.5 billion • Regulatory Approval Deadline: June 30, 2031 • Expected Closing: Around year-end 2025 🔍 Market Reaction Novo Nordisk’s stock (NYSE: NVO) opened at $59.63 on Thursday, with a market capitalization of $266.25 billion . #NovoNordisk #AkeroTherapeutics #Acquisition #MASH #MetabolicDiseases #PharmaceuticalNews Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Miroslav Gasparek 7mo Report this p
Akero Therapeutics Appoints Yuan Xu to its Board of Directors | citybiz Skip to content citybiz Cities Atlanta Baltimore Boston Charlotte Raleigh Chicago Cleveland Dallas Denver Detroit Global Houston Indianapolis Los Angeles New York Philadelphia Phoenix Pittsburgh Portland San Diego San Francisco Seattle South Florida Washington DC Channels Q&A citybiz+ People Commercial Real Estate General Business Mergers & Acquisitions Financial Services / Investment Firms Venture Capital Internet / Technology Law Bylines Thought Leadership Accounting Architecture and Construction Residential Real
DEF 14A 1 tm212663-1_def14a.htm DEF 14A tm212663-1_def14a - none - 6.4219144s TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ​ SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ​ Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ​ ☐ Confidential, for Use of the Commiss … reholdermeeting.com/AKRO2020, where you will be able to vote electronically and submit questions. You will need the 16-digit control number included with these proxy materials to attend the Annual Meeting. The purpose of the Annual Meeting is the following: 1. To elect three class II directors, Seth L. Harrison, M.D., Graham Walmsley, M.D., Ph.D, and Yuan Xu, Ph.D., to our board of directors, to serve until the 2024 annual meeting of stockholders and until his successor has b … l Meeting or any adjournment or postponement of the Annual Meeting. ​ The proposal for the election of directors relates solely to the election of class II directors nominated by the Board of Directors. Only Akero Therapeutics, Inc. stockholders of record at the close of business on April 5, 2021, will be entitled to vote at the Annual Meeting and any adjournment or postponement thereof. You can find more information on each of the matters to be voted on at the Ann … ; ​ GENERAL INFORMATION ​ ​ ​ ​ 2 ​ ​ PROPOSAL NO. 1 — ELECTION OF CLASS II DIRECTORS ​ ​ ​ ​ 7 ​ ​ PROPOSAL NO. 2 — RATIFICATION OF THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS AKERO’S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2021 ​ ​ ​ ​ 13 ​ ​ CORPORATE GOVERNANCE ​ … eeting.com/ ​ AKRO2021, where you will be able to vote electronically and submit questions. The board of directors of Akero Therapeutics, Inc. is using this proxy statement to solicit proxies for use at the Annual Meeting. In this proxy statement, the terms “Akero,” “we,” “us,” and “our” refer
%PDF-1.6 %���� 297 0 obj > endobj 308 0 obj >/Filter/FlateDecode/ID[ ]/Index[297 26]/Info 296 0 R/Length 77/Prev 1018913/Root 298 0 R/Size 323/Type/XRef/W[1 3 1]>>stream h�bbd```b``�����d6�dm��� �i=��"eI� '�� H��`e`bd`�����a���� endstream endobj startxref 0 %%EOF 322 0 obj >stream h��RAkA}���ئ�M�i],��B VD�X���w��R��T�M� ).�a@ VA/"��A$� UP� R(xĴ� �+�G�Mп��7|��y�ԑ��� LNny��8�ͱ�nVC�^���T�½��#�ڈ�P{:���`�^��$��X����9J^:v�%%��:����^ξ��0U�w���;���e�Ji k�h ���C|L\��v��z� v�ҿ�9��Ň|�����+K�K'O .���ř;�ԩbnt�fj��{�7?'�y��_د�ݬ��a����3z�jVM�V�-,4ܺ�ܜ-�Y�և���Q�6�f� … 00 2025-04-28T19:31:39-04:00 2025-04-28T19:33:17-04:00 Aspose.PDF for Java 22.2 application/pdf uuid:5dc9b19f-afe1-44f3-99a4-97ee91c215cf uuid:88344ab7-6052-4468-8821-eda305c18d02 endstream endobj 192 0 obj >stream H�b``������$��PPTR� ���~����� �� |@���T ��#��� 2 S /`MZ ��QJjq2�����%@q� [$)�.��C����&��� �^���ʢ��CKKKǔ��T������bϼ������Ē��Z� ��_������`h�J�� P8BX��A�!@riQ�V$�����Pɰ���4c� >stream h�_k�0��Q�2Ч�&͟��n*+c 2 FWt����~�{��6���k�&�s"
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Akero Therapeutics | Efruxifermin (EFX) for MASH | History Contact Linked Twitter About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors Select Page About Our Company Our History Leadership Contact Focus Therapeutic Areas Publications & Posters Efruxifermin (EFX) Clinical Trials Clinical Trials Overview Patients & Caregivers Careers & News Our Culture Job Opportunities News Investors
%PDF-1.4 %�쏢 %%Invocation: gs -sDEVICE=pdfwrite -dPDFSETTINGS=/printer -dCompatibilityLevel=1.4 -dColorConversionStrategy=/LeaveColorUnchanged -dDownsampleMonoImages=true -dDownsampleGrayImages=true -dDownsampleColorImages=true -dAutoFilterColorImages=true %%+ -dAutoFilterGrayImages=true -dColorImageFilter=/FlateEncode -dGrayImageFilter=/FlateEncode -dCompressFonts=true -dColorImageResolution=150 -dGrayImageResolution=150 -dMonoImageResolution=150 -dNOPAUSE -dQUIET -dBATCH ? ? ? 6 0 obj > stream x��}[s\7��"�eB=s��}��q�W�98�3��`[��n[�eu���}��"��D����gt�����d~�@�"�.���)\��H$2?���[U������
EX-10.9 9 a2238823zex-10_9.htm EX-10.9 Exhibit 10.9 CONFIDENTIAL CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. EXCLUSIVE LICENSE AGREEMENT by and between AMGEN INC. and AKERO THERAPEUTICS, INC. Dated as of June&n … ELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. TABLE OF CONTENTS ARTICLE 1. DEFINITIONS 1 ARTICLE 2. LICENSE GRANT 11 2.1 Grant 11 2.2 Sublicenses 11 2.3 Transfer of Licensed Know-How and Licensed Materials 12 2.4 Reserved Rights and Ongoing Activities 14 ARTICLE 3. FEES, ROYALTIES AND PAYMEN … ELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 8.3 Publications 32 8.4 Relationship to the Confidentiality Agreement 33 8.5 Attorney-Client Privilege 33 ARTICLE 9. TERM AND TERMINATION 33 9.1 Term 33 9.2 Termination by AMGEN 33 9.3 Termination by NEWCO 34 9.4 Termination Upon Bankruptcy 35 9.5 Effects of Term … ELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. EXCLUSIVE LICENSE AGREEMENT This EXCLUSIVE LICENSE AGREEMENT (this “ Agreement ”) is entered into as of June 7, 2018 (the “ Effective Date ”) by and between AMGEN INC., a Delaware corporation having an address at One Amgen Center Drive, … bute the Product based upon the same throughout the world, and AMGEN desires to grant such a license to AKERO in accordance with the terms and conditions of this Agreement; and WHEREAS , concurrently with the execution and delivery of this Agreement, the Parties are entering into (i) a stock purchase agreement with the other investors
I’m pleased to begin this week as Chief Executive Officer of Akero Therapeutics, a Novo Nordisk company. Having had the privilege of helping found this company and working alongside this team over… | Jonathan Young | 104 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update y
AKRO SEC Filings - Akero Therapeutics 10-K, 10-Q, 8-K Forms --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & Gas Defe … Schedule 13G/A showing that Deep Track Capital, Deep Track Biotechnology Master Fund, Ltd., and David Kroin now report beneficial ownership of 0 shares of Akero common stock, or 0.00% of the class , as of December 31, 2025 . The filing confirms they have no sole or shared voting or dispositive power over any Akero shares and that they own less than 5% of the company’s stock. The ownership calculations reference 82,316,179 shares outstanding as of November 3, 2025 , based on A … rring 9,259 shares of common stock at a reported price of $0 to a donor advised fund. In addition to direct ownership, the filing shows indirect ownership of 20,000 Akero shares in each of three irrevocable trusts for the benefit of the reporting person’s children, for a total of 60,000 indirectly held shares. The reporting person disclaims beneficial ownership of the trust-held securities, and notes that the stock options exercised are vested and currently exercisable. Rhea- … g 74,538 shares of Akero Therapeutics common stock as a gift to a donor advised fund on 11/20/2025. The transaction was reported with a price of $0, consistent with a non-cash charitable transfer rather than a market sale. Following this gift, the reporting person directly beneficially owns 436,837 shares of Akero Therapeutics common stock. This Form 4 filing documents the change in beneficial ownership for regulatory disclosure purposes and does not describe any open-market … cutive donated 37,100 shares of Akero common stock as a gift to a donor advised fund, with the transaction reported at a price of $0 per share, reflecting the non-sale nature of the transfer. After this charitable transfer, the reporting person beneficially owns 129,471 shares of Akero common stock in direct ownership form. This filing documents
Akero Therapeutics Appoints Tom Heyman to its Board of Directors Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Galle … velopments in the United States and foreign countries; the Company's ability to fund operations; as well as those risks and uncertainties set forth more fully under the caption "Risk Factors" in Akero's Annual Report on Form 10-K for the year ended December 31, 2019 and most recently filed Quarterly Report on 10-Q, as filed with the Securities and Exchange Commission (SEC) as well as discussions of potential risks, uncertainties and other important factors in Akero's other fi … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Investor highlights - Get an overview of our investor services Disease areas Science & technology Partnering Sustainable business Careers About us Our products Investors News & media Healthcare professionals Contact us Latest news {{'2026-06-11T15:30:50Z' | dateFormatFilter}} Novo Nordisk A/S: IT Security incident at Novo Nordisk Read more {{'2026-06-11T15:03:13Z' | dateFormatFilter}} Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK Read more {{'2026-06-07T21:31:24Z' | dateFormatFilter}} Novo Nordisk’s CagriSema 2.4 mg / 2.4
22nd Annual Educational Meeting in Gastroenterology - Cedars-Sinai - Continuing Education (CE) Gastroenterology</Profession><Profession>Internal Medicine</Profession><Profession>Family / General Medicine</Profession><Profession>Hepatology</Profession" /> Cedars-Sinai faculty members who have transitioned to a csmc.edu email address should not create a new CloudCME account if they experience login issues. Instead, please email [email protected] , and we will update your existing account with your new email address. 6/9/2026 12:00:00 AM {1} ##LOC[OK]## {1} ##LOC[OK]## # … Your Password ?" link. Forgot Your Password? Enter your Email address and click submit to have a login reset link sent to you. Back to Login {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]## Create an Account: (All fields are required) Email: First Name: Last Name: Password: Password: Password Requirements Must be between 8 and 16 characters in length Must Contain at least 1 upper case character Must Contain at least 1 lower case character Must c … cation (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Credits AMA PRA Category 1 Credit(s)™ (MD, DO) (12.50 hours), ABIM MOC Part 2 (12.50 hours), Non-Physician AMA Attendance (12.50 hours) Keywords: LIVE ABIM2 AMA MOC Gastroenterology Livestream The registration form for this activity is currently unavailable. Mitigation of Relevant Financial Relationship … nDex Pharmaceuticals|Speaker-AbbVie (Relationship has ended)|Other: Educational grant support-Pfizer, Inc. Stephen A Harrison, MD Pinnacle Clinical Research Faculty PrincipalNamedInvestigator-Viking|PrincipalNamedInvestigator-Axcella|PrincipalNamedInvestigator-Cirius|PrincipalNamedInvestigator-CiVi|PrincipalNamedInvestigator-Cymabay|PrincipalNamedInvestigator-Enyo|PrincipalNamedInvestigator-Galectin|PrincipalNamedInvestigator-Galmed Research and Dev|PrincipalNamedInvestigator … onsultant-Bausch Health|Stock Options or Shareholder-Synthetic Biologics|Other: Grant-Synthetic Biologics|PrincipalNamedInvestigator-Bausch Health|Consultant-Bausch Health|Consultant-Progenity|Consultant-Vivante Health|Consultant-Ferring|Consultant-Seres Therapeutics|Consultant-Ardelyx|Royalties or Patent Beneficiary-Aytu Biosciences|Royalties or
10-K false FY 0001744659 http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent http://fasb.org/srt/2024#ChiefExecutiveOfficerMember 0001744659 us-gaap:CommercialPaperMember 2023-01-01 2023-12-31 0001744659 us-gaap:RetainedEarningsMember 2024-12-31 0001744659 akro:AmendedSalesAgreementMember 2023-01-01 2023-12-31 0001744659 akro:CommonStockAvailableForAtmProgramMember akro:PfizerIncMember 2022-06-15 0001744659 us-gaap:FairValueInputsLevel3Member akro:WarrantLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 20 … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth compa … X, or placebo. The primary histology endpoint, for Cohort 1 only, to support an application for accelerated approval, is the proportion of patients experiencing ≥ 1-stage fibrosis improvement and resolution of MASH after 52 weeks of treatment. All patients in Cohort 1 and Cohort 2 will be evaluated for long-term clinical outcomes for up to 240 weeks of treatment. Results for the 52-week primary histology endpoint from the SYNCHRONY Histology trial are expected in the fi … welve years of market exclusivity from the approval date of a Biologics License Application, or BLA, in the United States. Our management team has extensive experience in drug discovery, development and commercialization, and has been involved in the approvals of more than 20 medicines. Our Chief Executive Officer, Andrew Cheng, MD, PhD, was formerly Chief Medical Officer at Gilead, and responsible for clinical development for Gilead's HIV program. Our Chief Development Offic … X, or placebo. The primary histology endpoint, for Cohort 1 only, to support an application for accelerated approval, is the proportion of patients experiencing ≥ 1-stage fibrosis improvement and resolution of MASH after 52 weeks of treatment. All patients in Cohort 1 and Cohort 2 will be evaluated for long-term clinical outcomes for up to
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Friends of Boyers Orchard - Our Sponsors MENU About Meet the Board Foundations Field Trips News Gallery Events Sponsor Fruits Volunteer Contact Donate Today! Sponsor a Tree Sponsor-a-Tree Started in 2022, Sponsor-A-Tree is a great way to help contribute to the orchard, learn more about fruit tree production and care, form a longer-term connection with a specific tree, and of course, celebrate the fruits of your labor! We encourage families, groups of friends, co-workers, and small businesses to go in on a tree sponsorship together. Overview: Sponsored trees are marked with a tag with the
Novo Nordisk has completed its acquisition of Akero Therapeutics - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Novo Nordisk has completed its acquisition of Akero Therapeutics December 10, 2025 | 2 min read Twitter LinkedIn Facebook Email Print Bagsværd, Denmark and South San Francisco, CA, US, 9 December 2025 – Novo Nordisk and Akero Therapeutics Inc. (“Akero”) (Nasdaq: AKRO) today announced that Novo Nordisk’s a … when you subscribe to GenePool! MORE ON THIS TOPIC Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst Mergers & acquisitions Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China June 24, 2026 · 2 min read · Tristan Manalac Mergers & acquisitions AbbVie strikes $10.9B Apogee buy to challenge … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manuf … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025 November 10, 2025 | 6 min read Twitter LinkedIn Facebook Email Print Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observ … ory developments in the United States and foreign countries; Akero’s ability to fund operations; as well as those risks and uncertainties set forth more fully under the caption "Risk Factors'' in Akero’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission (SEC) as well as discussions of potential risks, uncertainties and other important factors in Akero’s other filings and reports with the SEC. All for … when you subscribe to GenePool! MORE ON THIS TOPIC Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst Inflammatory bowel disease Merck posts ‘encouraging’ Phase 3 ulcerative colitis data but Roche challenge looms June 23, 2026 · 2 min read · Tristan Manalac BioSpace at BIO to find out" href="https://www.biospace.com/drug-develo … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio October 9, 2025 | 7 min read Twitter LinkedIn Facebook Email Print Acquisition adds potential first- and best-in-class asset, enhancing Novo Nordisk’s portfolio for treatment of MASH, one of the mo … n read · Jennifer C. Smith-Parker Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst Mergers & acquisitions Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China June 24, 2026 · 2 min read · Tristan Manalac Inflammatory bowel disease Merck posts ‘encouraging’ Phase 3 ulcerative … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Akero Therapeutics Launches with $65 Million Series A to Battle NASH - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Pr … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioMidwest Akero Therapeutics Launches with $65 Million Series A to Battle NASH June 25, 2018 | 3 min read | Mark Terry Twitter LinkedIn Facebook Email Print Akero Therapeutics, headquartered in Cambridge, Massachusetts, closed on a $65 million Series A financing round. Akero Therapeutics, headquartered in … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Akero Therapeutics Closes $65 Million Series A Financing to Advance New Treatments for Serious Metabolic Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tr … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Akero Therapeutics Closes $65 Million Series A Financing to Advance New Treatments for Serious Metabolic Diseases June 25, 2018 | 4 min read Twitter LinkedIn Facebook Email Print Financing led by Apple Tree Partners, Atlas Venture, venBio Partners and Versant Ventures CAMBRIDGE, Mass., June 25, 2018 /PRNewswire … nsformative life sciences businesses. The firm is actively investing its fourth fund, with $1.5 billion in capital commitments. ATP considers therapeutics and medical device investments at all stages, from discovery research through to commercialization and takes a long-term view to create sustainable value. For more information visit www.appletreepartners.com . About Atlas Venture Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing g … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Akero Therapeutics Appoints Yuan Xu to its Board of Directors - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Rel … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Akero Therapeutics Appoints Yuan Xu to its Board of Directors April 26, 2021 | 4 min read Twitter LinkedIn Facebook Email Print Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), to … velopments in the United States and foreign countries; the company's ability to fund operations; as well as those risks and uncertainties set forth more fully under the caption "Risk Factors" in the company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (SEC) as well as discussions of potential risks, uncertainties and other important factors in the company’s other filings and reports with the SEC. All forward-looking statements … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Akero Therapeutics to Present at H.C. Wainwright's 4th Annual NASH Virtual Investor Conference - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Bay Akero Therapeutics to Present at H.C. Wainwright’s 4th Annual NASH Virtual Investor Conference September 28, 2020 | 1 min read Twitter LinkedIn Facebook Email Print Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alc … when you subscribe to GenePool! MORE ON THIS TOPIC Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kinder-and-gentler-join-biospace-at-bio-to-find-out" > Antibody-drug conjugate Can ADCs be kinder and gentler? Join BioSpace at BIO to find out June 23, 2026 ·&n … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Efruxifermin Granted FDA Breakthrough Therapy Designation for NASHDesignation based on Akero’s Phase 2b HARMONY study - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Jo … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News FDA Efruxifermin Granted FDA Breakthrough Therapy Designation for NASHDesignation based on Akero’s Phase 2b HARMONY study December 8, 2022 | 7 min read Twitter LinkedIn Facebook Email Print Akero Therapeutics, Inc. has received a Breakthrough Therapy Designation from the US Food and Drug Administratio … ory developments in the United States and foreign countries; Akero’s ability to fund operations; as well as those risks and uncertainties set forth more fully under the caption "Risk Factors" in Akero’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission (SEC) as well as discussions of potential risks, uncertainties and other important factors in Akero’s other filings and reports with the SEC. All forw … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Akero Bounces Back in MASH, Posts Positive Mid-Stage Fibrosis Data - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Pres … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Akero Bounces Back in MASH, Posts Positive Mid-Stage Fibrosis Data March 4, 2024 | 2 min read | Tristan Manalac Twitter LinkedIn Facebook Email Print Pictured: 3D illustration of a damaged liver/iStoc New 96-week data show Akero Therapeutics’ efruxifermin can improve fibr … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin